ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Genitourinary Cancers Symposium

Share this content:
Neal D. Shore
Neal D. Shore

In anticipation of the 2013 Genitourinary Cancers Symposium, which begins February 14 in Orlando, Florida, ChemotherapyAdvisor.com Editorial Board member Dr. Neal Shore, MD, FACS, has recommended nine abstracts that are most significant in terms of clinical impact for the practicing oncologist.

Dr. Shore is Director, CPI, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.


Abstract #5
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy
Dana Rathkopf

Abstract #6
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor
Howard I. Scher

Abstract #7
General Poster Session A: Prostate Cancer; Oral Abstract Session A: Prostate Cancer (eQ&A)
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC)
Matthew Raymond Smith

Abstract #11
General Poster Session A: Prostate Cancer
Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
Nicholas J. Vogelzang

Abstract #18
General Poster Session A: Prostate Cancer
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer
Bertrand Tombal

Abstract #22
General Poster Session A: Prostate Cancer
Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data
Charles J. Ryan

Abstract #114
General Poster Session A: Prostate Cancer
A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
Eric Jay Small

Abstract #350

General Poster Session C: Renal Cancer
Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma

Robert John Motzer

Abstract #306

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
A multi-analyte assay for the noninvasive detection of bladder cancer

Makito Miyake

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs